The presentation, which is part of the Pitch & Partner track of the congress, will focus on SFX-01, the Company's lead product, in the treatment of subarachnoid haemorrhage ("SAH"). SFX-01 is currently in a Phase II clinical trial in SAH, which remains on track to report around the end of 2018.
The presentation will also refer to the ongoing Phase II trial of SFX-01 in metastatic breast cancer, which is on track to report an interim read-out in Q2 this year with the final read-out around the year end.
The World Orphan Drug Congress USA 2018, which will take place on 25-27 April 2018, focuses on all aspects of orphan drug development and rare disease research. Further details are available at the congress website: http://www.terrapinn.com/conference/world-orphan-drug-congress-usa/index.stm.
This will be the second international forum that Steve Franklin has been invited to address this month, having just returned from a closed meeting in Madrid where he presented the "SFX-01 for Subarachnoid Haemorrhage" clinical programme to senior scientists from pharmaceutical companies and academia, all with a common interest in the Nrf-2 pathway.